Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 303

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 303
---
 United States. Following FDA approval to market GelrinC
in the United States, the Company will pay Baxter $200 per year during the term of this Services Agreement; however, the year the Company
will receive an FDA approval to market GelrinC in the United States, the Company must pay the remining $140 balance for that year within
30 days after receiving such approval. The Company incurred expenses under the Services Agreement of $30 in each of the six months ended
June 30, 2025 and 2024.

| 3. | In July 2008, the Company                                                                                                                 
 entered into a Supply Agreement with Baxter and Teva which was amended and restated on January 6, 2009, pursuant to which the Company     
 agreed to purchase Tisseel VHSD fibrin sealant Kit (the “Tisseel”), from Teva, with Teva being Baxter’s exclusive                         
 distribution agent in Israel for Tisseel, for manufacture of GelrinC. The Supply Agreement was amended and restated. The Supply Agreement 
 provides for up to 1,000 kits of Tisseel of the 2 ml Tisseel kit, or 500 kits of Tisseel of the 4 ml Tisseel kit, or 200 kits of          
 Tisseel the 10 ml Tisseel kits per year at a fixed purchase price of $0.136 per unit. The payments under the Supply Agreement are         
 due 30 days from the date of invoice and the Company is subject to a service charge of 1% per month on all amounts past due.              |

The Supply Agreement had an initial
term of 3 years which ended on April 1, 2011; however, the Supply Agreement has an ever-green clause and is automatically renewable for
consecutive 1 year terms unless either party gives notice of termination at least 3 months prior to the then current term. The Supply
Agreement may be terminated without cause by Baxter upon 90 days’ prior written notice to the other parties. In addition, either
party may terminate the Supply Agreement in the event of an uncured material breach or insolvency.

| 4. | In January 2025, the                                                                                                              
 Company renewed its facility lease agreement until December 2025. The monthly rental obligations under non-cancellable leases are 
 approximately $5.5 (including $3 for administrative expenses).                                                                    |

As part of the agreement, the Company
has provided the landlord with a bank